Aim . A goal of this noninterventional prospective multicenter observational program was to evaluate efficacy and safety of josamycin in patients with nonsevere communityacquired pneumonia (CAP) in routine clinical practice. Methods. Patients (n = 104) with radiological signs of pneumonia were treated with josamycin (Wilprafen® Solutab®, dispersible tablets 1 000 mg). Complete resolution of CAP was achieved in 95.6 % of patients, a clinically significant improvement was seen in 3.3 % of patients and a lack of effect was seen in 1 (1.1 %) patient. Radiological followup did not reveal worsening in any patients. The results of this study have demonstrated that josamycin was highly effective (> 95 %) and had a good safety profile in outpatients with nonsevere CAP.